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Abstract
Background: Telemedicine has been advocated as an effective means to provide health care
services over a distance. Systematic information on costs and consequences has been called for to
support decision-making in this field. This paper provides a review of the quality, validity and
generalisability of economic evaluations in telemedicine.
Methods: A systematic literature search in all relevant databases was conducted and forms the
basis for addressing these issues. Only articles published in peer-reviewed journals and written in
English in the period from 1990 to 2007 were analysed. The literature search identified 33
economic evaluations where both costs (resource use) and outcomes (non-resource
consequences) were measured.
Results: This review shows that economic evaluations in telemedicine are highly diverse in terms
of both the study context and the methods applied. The articles covered several medical specialities
ranging from cardiology and dermatology to psychiatry. The studies analysed telemedicine in home
care, and in primary and secondary care settings using a variety of different technologies including
videoconferencing, still-images and monitoring (store-and-forward telemedicine). Most studies
used multiple outcome measures and analysed the effects using disaggregated cost-consequence
frameworks. Objectives, study design, and choice of comparators were mostly well reported. The
majority of the studies lacked information on perspective and costing method, few used general
statistics and sensitivity analysis to assess validity, and even fewer used marginal analysis.
Conclusion: As this paper demonstrates, the majority of the economic evaluations reviewed were
not in accordance with standard evaluation techniques. Further research is needed to explore the
reasons for this and to address how economic evaluation in telemedicine best can take advantage
of local constraints and at the same time produce valid and generalisable results.
Background
There is a growing interest in shifting health care delivery
from costly secondary care hospitals to community set-
tings bringing care 'closer to home' for patients [1]. Tele-
medicine has been advocated as an effective means to
deliver health services to remote communities. Telemedi-
cine can be defined as 'distance medicine' using informa-
tion and communication technologies (ICT) to examine,
monitor, treat and care for patients over a distance. Differ-
ent applications can be used both within and between all
kind of health care institutions as well as to monitor and
provide support to patients living at home. Telemedicine
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can also be used to improve the chain of care and may
involve complex delivery systems that employ a mix of
technologies in addition to innovative clinical processes
[2]. Recent telemedicine applications encompass activities
such as remote consultations in a wide range of speciali-
ties ranging from dermatology and cardiology to psychia-
try. Other examples are transmission of echocardiograms,
blood glucose levels, and x-rays; provision of accident and
emergency expertise to remote locations; remote support
and monitoring of patients undergoing dialysis; remote
fetal monitoring; support and care to elderly people or to
patients with chronic conditions living at home. In this
review, telemedicine refers to technologies used in direct
patient care such as real-time videoconferencing and
store-and-forward applications. The former involves live
sound and picture. The latter involves asynchronous
transmission of medical data such as video films (ultra-
sound), still- images (x-rays, photographs of skin lesions
and other static images) and sound files (heart murmurs).
As with any other form of health care technology there is
a need to assess effectiveness, efficiency and safety before
it is brought into wider use [3]. Telemedicine evaluation
should first ensure that the technology is safe and gener-
ates as much benefit as conventional care. If using the
technology produces equal or better health or quality of
life, the next step is to analyse differences in costs (one
should note, however, that services could generate less
benefit at lower cost and still be considered cost-effective).
Cost savings and other benefits of telemedicine are often
suggested by the logic of its impact on health care delivery
and by the optimistic promise of ICT in general [2]. Sys-
tematic information on costs and consequences has been
called for to support decision-making both in order to
control health care spending; and to document value for
money to facilitate reimbursement of telemedicine activi-
ties.
Economic evaluation is a set of formal analytical tech-
niques that provide systematic information about costs
and benefits of alternative options, and can thereby assist
in priority-setting [4-7]. If economic evaluation is advo-
cated as an important support tool for decision-making, it
seems appropriate to monitor the quality of these evalua-
tions. This will also provide a better understanding of eco-
nomic evaluation applied to telemedicine. Several
systematic reviews have found little evidence that tele-
medicine is cost saving [8-10]. Reviewers noted few rigor-
ous evaluations and even useful studies had some
questionable use of standard techniques for economic
evaluations [2,11-13]. High-quality evidence of the tech-
nologies' impact on patients' health and well-being is also
lacking [3,9,14].
Other systematic reviews investigating the cost effective-
ness of telemedicine found that most studies evaluated
benefits in terms of cost savings with no assessment of
changes in the benefits for patients [8,13]. This review
explores whether more recent evaluations have included
patient outcomes and it analyses only full economic eval-
uations, i.e. evaluations where both costs (resource use)
and outcomes (non-resource consequences) have been
measured and valued.
The purpose of this paper is to provide a detailed review
of full economic evaluations of telemedicine use. This
qualitative assessment has three objectives: to provide
detailed information on evaluation approaches and
applied methods; to assess the quality of the evaluations
and their potential contribution to priority setting; and to
discuss the applicability of best-practice methods to tele-
medicine settings. The focus is on exploring the following
aspects: clarity of study objective; adequacy of compari-
son; choice of study perspective and design; measuring
and valuation of costs and outcomes; reporting of data
sources; handling of uncertainty; presentation of results.
Methods
Selection criteria
A systematic literature review was conducted to identify
all published articles describing economic evaluation of
telemedicine use. It is clear from the literature that tele-
medicine encompasses a wide range of different technol-
ogies and services used in a variety of medical settings. In
this review telemedicine refers to the use of information
and communication technologies in direct patient care,
i.e. it covers only aspects in which the patient is directly
involved and the patient and provider are separated by
distance. Services that did not require encounters between
patients and providers, such as radiology and pathology
were therefore excluded. Technologies of interest were
audio and visual (i.e. videoconferencing) or just visual
(still-image telemedicine) or audio and data transfer
(monitoring) excluding telephone calls without any trans-
fer of medical data, traditional e-mails, and information
and support sites on the Internet. This restriction has been
imposed to make the review process more manageable
and corresponds to a previous review [3].
Only articles written in English from 1990 to 2007 were
included. These must have been published in peer-
reviewed journals. This excluded books, HTA reports and
unpublished materials. The articles included were full
economic evaluations, i.e. they undertook a comparative
analysis of both costs as resource use and outcomes in
form of non-resource consequences of at least two alterna-
tives, (or one if it was a cost-benefit study). The non-
resource consequences typically refer to the effect that
alternative interventions have on peoples' health status.Cost Effectiveness and Resource Allocation 2009, 7:18 http://www.resource-allocation.com/content/7/1/18
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The articles included described either applied studies, i.e.
they generated primary data, or studies in which second-
ary data was modelled. Cost analyses where the conse-
quences of two interventions were assumed to be identical
across the alternatives were excluded. In this review, eval-
uations using outcome measures such as successful tele-
medicine consultations, travels avoided, hospitalisations
avoided and other avoided costs have been categorised as
cost analyses and excluded.
Search strategy
A literature search was undertaken using the British
National Health Service Economic Evaluation Database
(NHS EED), PubMed, PsychInfo, Embase, CHINAL, Ovid
Nursing, British Nursing Index, ISI-Web of Knowledge,
EconLit and Telemedicine Information Exchange. The two
main journals in the telemedicine field, 'Journal of Tele-
medicine and Telecare' and 'Telemedicine Journal and E-
health', in addition to the reference lists in the retrieved
articles and existing reviews, have been manually
searched.
The search strategy included the Thesaurus terms "tele-
medicine" (including all subheadings) and "videoconfer-
encing" (as a single term) and various other relevant text
words. This search strategy was combined with Thesaurus
"Costs and Cost-analyses" (including all subheadings).
The latter is one hierarchical level above "Cost-benefit
analysis" in the sub-tree, has a high sensitivity and has
been recommended as a search strategy to identify eco-
nomic evaluations [15,16]. When medical subheading
terms were not available, the term was searched as a key-
word. The search strategy in the non-medical database
included text searches using "telemedicine", "telehealth",
"remote consultations", "videoconferencing", "telecon-
sultations" and "telecare", while "cost", "cost analysis",
"cost-effectiveness" and "economics" were included in the
Telemedicine Information Exchange search. As a supple-
ment, free-text searches in the medical databases with the
search terms mentioned above were also conducted to
include the more recent economic evaluations.
Review process
Selection of relevant publications was based on informa-
tion found in the abstracts. Full-text articles were retrieved
when the abstract indicated analyses of both costs and
non-resource consequences. Full-text was also retrieved
for closer inspection if the abstract did not provide clear
indication of the content. All abstracts and full-text arti-
cles were read by the author.
Data were extracted from the full-text articles based on
international benchmarks on conducting and reporting of
economic evaluations [7,17]. Such recommendations
often have forms as checklists and these identify key
parameters that one may expect to find in well-executed
studies. The main parameters used to assess the articles
reviewed in this paper were clarity of study objective, ade-
quacy of comparison, choice of study perspective and
design, transparency in the measurements and valuation
of costs and outcomes, reporting of data sources, handling
of uncertainty, and presentation of results. These evalua-
tion criteria have been chosen because they reflect the
main challenges in telemedicine evaluations reported in
the literature [2,18]. In addition, details on the interven-
tion type, medical field, type of analysis, and key findings
have been collected (see Additional file 1). The complete
data table is obtainable from the author on request.
Results
Summary of economic studies in telemedicine
The literature search identified 779 abstracts which were
reviewed for relevance. For 89 of these, full-text articles
were retrieved. After review, 33 articles were found to meet
the inclusion criteria, i.e. they measured both costs and
consequences of telemedicine.
Additional file 1 provides an overview of the studies
included in this review. The articles covered several differ-
ent medical specialities ranging from dermatology and
cardiology to psychiatry. The use of telemedicine was
most common in diabetes care (n = 6) and cardiology (n
= 6). Almost half of the studies evaluated telemedicine in
home care (n = 15), the rest evaluated services provided
either in secondary care or between primary and second-
ary care institutions. The services provided used a variety
of different technologies ranging from store-and-forward
telemedicine (n = 16) to real-time videoconferencing (n =
7) and a combination of the two (n = 10) (see Additional
file 1 for details). One third of the studies (n = 11) were
published in the two main telemedicine journals: 'Journal
of Telemedicine and Telecare' and 'Telemedicine and e-
Health', while the others were published in a variety of
medical and health research journals.
Study objective and comparators
A clear description of the study objective together with
information on the comparators is vital for assessing the
quality of an economic evaluation. This will provide the
reader with information both on the aim of the evaluation
and on the decision-making context. In the majority of
the studies (n = 28) the objectives were stated in a clear
and unambiguous manner and mainly addressed choice
of techniques as well as cost-effective resource allocations.
One study stated clearly that the main objective was to test
the feasibility of the technology [19]. All but six studies
[20-25] provided a clear description of the comparators
and sufficient information on the study groups (who
received what). Almost all studies (n = 32) compared tele-
medicine to at least one alternative without telemedicine.Cost Effectiveness and Resource Allocation 2009, 7:18 http://www.resource-allocation.com/content/7/1/18
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This was referred to as a "usual care or current alternative"
in some kind of on-site encounter. This is a relevant and
appropriate comparator as it reflects the conventional
approach to patient management. One study compared
two different telemedicine techniques which appeared
appropriate in their context [26]. In six studies telemedi-
cine was analysed as a complement to traditional home
care [21,27-31], while in another three, it was unclear if
telemedicine was provided in addition to or instead of
usual care [23-25].
Study design and perspective
The majority of the studies reviewed were trial-based or
observational and included randomised controlled trials
(n = 13), non-randomised trials (n = 2), case control stud-
ies with the controls receiving standard care (n = 3),
before and after studies (n = 3), case series (n = 1) and
crossover trials with one group (n = 2) (see Additional file
1 for details). One study used two groups, but no informa-
tion on study design was provided [25], one study used
matched controls [32] and one study compared before
and after results from different patients, which the authors
acknowledged as a limitation [33].
Six of the evaluations were decision-modelling studies
using secondary data to analyse costs and consequences
(see Additional file 1). Five of the studies involved a liter-
ature search to obtain the primary studies [34-38], while
one study used results from one single study to derive the
effectiveness evidence [39]. None of the studies provided
information on the search strategy, the inclusion criteria
or the method used to extract relevant data (one study
reported a MedLine search [37]). The number of primary
studies ranged from four to 14. Three studies did not pro-
vide information about the model used [35,37,39], two
used decision-tree modelling [36,38] and one used a
Markov model [34]. The modelling studies analysed tele-
medicine as a means to support diabetes care [34,38], pre-
hospital care [35,37], dermatology [39] and paediatric
ophthalmology [36].
Two studies reported use of a societal perspective [35,40],
eight reported a health provider perspective [27,33,34,36-
39,41] and two reported a combination of health provider
and patient perspectives [42,43]. One of the studies which
reported a societal perspective only included direct health
care costs [40] while the other also included costs borne
outside the health care system (police, lawsuits and insur-
ance) [35]. Two thirds of the studies (n = 21) did not
explicitly report the study perspective.
Costing
The costs of telemedicine can be divided into two broad
categories: health care costs and non-health care costs.
Direct health care costs refer to the physical health
resources required to produce a specific health service or
programme. Non-health care costs are those outside the
health care sector, for example time costs such as produc-
tion loss or lost leisure time, travel costs and costs associ-
ated with childcare. All studies in this review measured
direct health care costs. These included costs related to
investment, installation, call costs, personnel costs, and
other health care costs. In addition, travel costs for health
care personnel were included if a visiting service or home
care was the alternative to telemedicine (n = 8) [27-
29,31,32,34,39,44]. Fewer than half of the studies (n =
11) estimated private travel costs and even fewer esti-
mated time costs as production losses (n = 8) (see Addi-
tional file 1 for details). For the majority of the studies (n
= 22) the patient did not travel or the health provider (for
example federal agencies in the US) paid for travel (n = 3)
[29,34,39]. Five studies provided no [45] or very limited
information [24,30,32,37] on the costs included, and in
almost half of the evaluations (n = 14) the costing method
was unclear. Fifteen studies provided details on resources
consumed in physical units and reported prices or unit
costs separately from quantities. Five of these reported
only certain costs and quantities separately.
The studies reviewed appeared to have used some combi-
nation of an 'ingredients' approach and an 'activity' based
approach to costing. The former is a costing method
where every cost item is broken down into its underlying
components, while the latter does not and refers to, for
example, the costs of a hospital bed-day without any fur-
ther information. An 'ingredients' approach was used to
calculate the cost of providing the telemedicine service or
the intervention, while 'activity' based costing was mainly
used to calculate hospital costs and the costs of home care
visits. This combination of 'ingredients' and 'activity'
approaches is common in economic analyses in health
care in general [46]. Three studies used an 'activity'
approach only [24,27,37].
In one third of the studies (n = 10) some of the cost items
were calculated using charges or reimbursement fees
[19,22,24,25,27,33,34,41,47,48]. These were mainly hos-
pital in-patient costs, costs of outpatient visits and costs of
home care visits. One study estimated the hospital costs as
a cost-to-charge ratio [33], which is a method that calcu-
lates costs using prices adjusted for excess profit and is
mainly used in the US [6]. For the majority of the studies
(n = 18) it was not possible to determine how hospital
costs had been valued. One study reported the use of an
anecdotal costing method and estimated hypothetical
hospital savings [49]. The costs of providing the telemed-
icine service were calculated using market prices and aver-
age staff wages. Time costs for patients and relatives were
valued using different shadow prices ranging from actual
loss of earnings [50], to estimates of production loss usingCost Effectiveness and Resource Allocation 2009, 7:18 http://www.resource-allocation.com/content/7/1/18
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the friction method [51]. One study estimated lost earn-
ings, lost overtime and lost unpaid work [43].
Tariffs or user fees do not necessarily reflect the true
opportunity costs of resource use. Only two studies
addressed the potential limitation of using charges to esti-
mate the costs of an intervention [27,33]. None of the
studies assessed telemedicine costing in relation to pro-
duction capacity or cost sharing. Only three studies
reported calculation of marginal costs [21,41,50].
Measuring the consequences
Additional file 1 shows that there is considerable variation
in the measures used to assess the non-resource conse-
quences in economic evaluations of telemedicine. The
effectiveness measures presented in the studies ranged
from impacts on process to final outcomes. The measures
varied from diagnostic accuracy, blood glucose levels,
anxiety and depression levels, physical capacity and
health-related quality of life (HRQL) to life-years gained
(LYG) and quality-adjusted life-years (QALYs).
Examples of process measures presented in the studies
include diagnostic accuracy and agreement in reading of
transmitted data (n = 5), medication compliance (n = 2),
time spent on diabetes care for both patient and profes-
sionals (n = 1), number of days to independent pouch
change after abdominal surgery and colostomy (n = 1)
and length of stay (n = 3) (see Additional file 1 for
details). Examples of disease-specific surrogate measures
used were blood glucose levels, hypoglycaemic events,
percentage reduction in wound size and body mass index.
These are all measures that can be related to future health
status. Seven studies used generic health-related quality of
life measures (SF-36 and EQ-5D), of which two studies
also used disease- or group-specific QoL-instruments
[42,52]. Other generic outcome measures employed in
the reviewed studies were return to activities of daily living
(n = 3), mortality in the form of death avoided or life-
years gained (n = 5) and QALYs gained (n = 4). One study
measured disability-adjusted life-years gained [22]. The
majority of the studies (n = 24) used multiple outcome
measures to evaluate effectiveness. Of the trial-based stud-
ies, three used secondary data to measure effectiveness, i.e.
the effectiveness data was reported in different articles
[23,43,50].
Other technical issues
The studies reviewed varied with regard to whether they
reported their data sources or not. Four of the studies did
not report data sources for either costs or consequences
[19,25,32,49]. All the remaining studies reported the
sources for the effectiveness data (n = 29). These were, for
example, questionnaires, existing literature, patient chart
records, case notes, and other clinical databases. The
sources for the cost estimates were explicitly reported in
most of the studies (n = 25). These were hospital account-
ing systems, project diaries, patient charts, case notes and
official databases. Four of the studies reporting data
sources for the effectiveness data did not report sources for
the cost data [30,39,45,47]. The modelling studies used
existing literature, official statistics, and databases; and
some included expert and author opinions (see Addi-
tional file 1 for details).
Fewer than half of the studies (n = 13) [22,23,31,34-
40,42,51,53] included sensitivity analysis to assess the
robustness of the findings to variability in parameters or
model inputs. One-way analyses were performed in nine
studies [22,23,36-39,42,51,53], multi-way sensitivity
analysis was performed in one study [35] and both types
of analyses were performed in three studies [34,40,43].
The majority of the studies (n = 23) used some kind of sta-
tistical analyses to calculate confidence intervals around
point estimates for the outcome measures. Three
employed non-parametric bootstrapping to estimate con-
fidence intervals around mean costs [42,43,51]. In four
studies costs were treated deterministically with no need
to account for the variability in the cost estimates
[19,21,32,39]. Of the total studies, less than one third (n
= 10) applied sensitivity analysis, together with appropri-
ate statistics to address the variability in both the effective-
ness measure and the costs (where these were not treated
deterministically).
Costs and consequences were summarised in a cost per
effect measure in less than one third of the studies (n = 9)
[22,34,35,37-40,45,51]. Incremental cost-effectiveness
ratios were calculated in five studies [34,38,39,45,51].
Five studies were CUAs while the rest were CEAs. Of the
latter, four reported use of cost-minimisation techniques
(CMA), and 19 took disaggregated forms and employed a
cost-consequence framework (CCA) (see Additional file 1
for details). The latter lists all the different outcomes
together with the costs instead of using a one-dimensional
outcome measure. The costs in these studies were calcu-
lated as total costs, annual costs or unit costs. The latter
were most frequently presented as a cost per patient or a
cost per visit/session (n = 15).
It is important to consider whether the costs and conse-
quences of interventions and their alternatives can be
adapted from one context to another. Only six studies
explicitly addressed the issue of generalisability to other
settings [21,34,35,38-40]. Another two studies included
extensive sensitivity analyses [43,51], which improved the
external validity. Limitations are however acknowledged
in the majority of the studies (n = 18) with statements that
aspects such as a retrospective design, too small sample
size, the use of charges and fees, a high drop-out rate andCost Effectiveness and Resource Allocation 2009, 7:18 http://www.resource-allocation.com/content/7/1/18
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wide confidence interval might limit the validity of the
results.
Discussion
This review shows that economic evaluations in telemed-
icine are highly diverse in terms of both the study context
and methods applied. The articles covered several medical
specialities and analysed telemedicine in home care as
well as in primary and secondary care settings using a vari-
ety of different technologies. Most studies used multiple
outcome measures and analysed the effects using disag-
gregated cost-consequence frameworks.
One of the main arguments for using telemedicine is that
these technologies have the potential to reduce health care
costs and enable cost-effective resource allocation. This
review identified 33 full economic studies measuring both
costs and consequences. The fact that only articles in Eng-
lish and published in peer-reviewed journals (to provide
some basic quality control) were included is recognised as
a limitation.
Even if the evidence base for telemedicine decisions is
alarmingly scarce, to simply increase the number of eco-
nomic studies in telemedicine must be considered in rela-
tion to a number of concerns highlighted by findings in
both this and other reviews [2,11]. Decision-makers need
to be confident that the economic studies in telemedicine
are consistent and reliable. Only eight studies [34,36,38-
40,42,50,51] had addressed all the key issues described in
the Method section (a clear study objective, adequate
comparison(s), reporting of study perspective and design,
transparent measurements and valuation of costs and out-
comes, reporting of data sources, addressing of uncer-
tainty and clear presentation of the results). The
remaining studies had several shortcomings primarily
concerning technical aspects and reporting of results.
Objectives, study design and choice of comparators were
mostly well reported. The majority of the studies lacked
information on the perspective, few used general statistics
and sensitivity analysis to assess validity, and even fewer
used marginal analysis. The effectiveness measures
appeared more consistent and well reported than the cost-
ing, which was often unclear. Some of these methodolog-
ical issues will be addressed in more detail below, along
with implications and recommendations.
Measuring effectiveness and patient safety
In some settings, telemedicine services are replacing tradi-
tional in-person encounters between patients and health
care personnel. In these situations disease- or case-specific
measures are sufficient to estimate the relative effective-
ness of telemedicine versus conventional approaches to
patient management. These measurements can even be at
an ordinal level. If specific outcome measures show equal
or better patient outcomes than usual care, then the next
step is to assess the differences in costs using standard
costing techniques. This approach to telemedicine evalua-
tion will however limit generalisability and make it
impossible to compare or synthesise results from evalua-
tions with different disease-specific outcome measures.
Telemedicine can also be used to provide a completely
new service alongside traditional care such as monitoring
of chronic conditions for patients living at home. In these
situations telemedicine is provided in addition to tradi-
tional home care and could potentially improve patients'
health. For example, if investing in telemedicine costs
more and is more effective, the decision-maker would
need information on how much more beneficial it is for
the costs involved. To be able to compare this with other
services and programmes generic health status measure-
ments such as QALYs or LYG are required.
Consistency in effectiveness measures has important
implications for the usefulness of cost effectiveness results
to decision-making [5]. This review found outcome meas-
ures ranging from diagnostic accuracy, blood glucose lev-
els, and quality of life measures to QALYs. Diagnostic
accuracy was frequently used together with surrogate
measures. The former will ensure quality of the transmit-
ted information. The latter is related to future health and
can be viewed as inputs into a health production function
[54]. If the objective of using telemedicine technologies in
diabetes care is to reduce and stabilise blood glucose lev-
els, it seems appropriate for the endpoint to measure
blood glucose levels. On the other hand, it can be difficult
to interpret cost-effectiveness in terms of a specific cost per
reduction in blood glucose level. Another example is if the
decision is whether to invest in telemedicine in dermatol-
ogy or not, the consequence measure employed can be
intermediate and case-specific, i.e. related to skin prob-
lems. While these examples are acceptable for assessing
technical efficiency, (i.e. how to produce a given level of
health outcome at least cost) this will not help in deciding
how to allocate resources across programmes. In these sit-
uations, generic health measures are required to allow for
comparison between the two such as LYG or QALYs. Few
studies used such generic health measures. One reason for
this may be that these are not sensitive enough to detect
small changes in health outcomes which telemedicine
services most likely produce. Another reason may be that
most economic evaluations have been undertaken to jus-
tify decisions within clinical areas and to support reim-
bursement and payment systems, and not as a basis for
broader decision-making.
Inclusion of non-health care costs
In the economic evaluation of telemedicine, the distinc-
tion between costs incurred within or outside the healthCost Effectiveness and Resource Allocation 2009, 7:18 http://www.resource-allocation.com/content/7/1/18
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care system seems particularly relevant. One argument for
promoting telemedicine is that the technology has poten-
tial to generate cost savings that are mainly outside the
health care system. In many health care systems, it is the
patients who pay the travel costs that telemedicine elimi-
nates, while the time savings are often valued as produc-
tion changes. The stakeholders bearing the costs may
differ from those experiencing the benefits, which in most
cases are patients and employers. To include non-health
care costs however requires the measurement of opportu-
nity costs to society and not just the opportunity costs as
health benefits forgone. These savings are excluded if one
adopts a health provider perspective. It is therefore impor-
tant to be clear about the viewpoint chosen for the analy-
sis and how this affects the results. This will also help the
reader judge whether all the relevant costs are included.
Few of the reviewed studies did explicitly report their
study perspective. It was however possible to infer the
viewpoint in most studies. Not reporting the perspective
explicitly is a common failing in economic evaluations in
general, even if the costs included are clearly presented
[5].
Lack of transparency in costing methods
The costs included in the reviewed studies were mainly
direct health care costs and direct non-health costs. The
former referred to the costs associated with providing the
alternatives while the latter were time costs and travel
costs. In some studies however, it was impossible to tell
the type and magnitude of the costs items included. More
than half of the studies provided limited or unclear cost
information and did not present unit cost data alongside
resource data. This could make it difficult for the reader to
assess whether all appropriate costs were included and to
judge whether the cost results could be adapted to their
own setting. It also appeared that in some studies the total
cost per visit differed from the cost per patient. Another
challenge is the inclusion and valuation of time costs.
Very few studies provided any reasons for including time
costs. For example, one study gave no rationale for includ-
ing time costs for patients or their families and friends
[21]. Another study included lost work and lost overtime
in addition to lost unpaid time [43]. A third study
included time costs for the patients in a sensitivity analysis
[39]. Presenting non-health care costs separately from
health care costs in a sensitivity analysis may seem more
appropriate, implying that the former may have less direct
impact in decisions. In practice, patients may already be
off work because of their health condition, leaving the
actual production loss unchanged. There is however, a
low level of agreement in the literature about whether to
include productivity changes or not [7,55,56].
A clear study objective and relevant comparators are
important, since economic evaluation is concerned with
measuring the marginal costs and benefits relative to their
highest valued alternative use [55]. In some analyses it
was unclear whether telemedicine was provided in addi-
tion to or as a substitute for traditional health care. In one
of the studies, it appeared that telemedicine visits were
provided in addition to regular home visits without the
costs of the latter being accounted for in the telemedicine
alternative [31]. To compare the cost per visit for telemed-
icine and home visits will be misleading if these costs dif-
fer from the total cost per patient. On the other hand, in a
real clinical situation it seems unlikely that telemedicine
could be a complete substitute for in-person encounters;
some combination of the two will probably be required.
Similarly, analysing two different telemedicine alterna-
tives without comparison to a current alternative will not
produce relevant information if the objective is to decide
whether to invest in or reimburse telemedicine services.
To calculate the cost of, for example, an outpatient consul-
tation or a hospital bed-day is often time consuming and
costly. Since most evaluations operate within budget con-
straints, it is easier to use readily available cost data such
as charges or tariffs. Even if these are often used to calcu-
late hospital costs [6] in most health care systems they are
only financial parameters with no relation to actual
resource consumption. In health systems with both tariffs
and lump sum financing, tariffs may cover only part of the
total cost of an activity. Hospitals are often multi-product
organisations with a high degree of cross-subsidies and
tariffs may therefore only be vehicles for funding activi-
ties. Only a few studies acknowledge that using charges
could limit the validity of their findings.
Generalisability
One of the main challenges in all economic evaluations is
to balance the need for internal validity against the ability
to generalise results to other settings. One third of the
studies reviewed were evaluations alongside randomised
controlled trials (RCT). RCT is a design with stringent cri-
teria for selecting participants and a strict compliance to
the study protocol, minimising potential bias. The RCT
may however not be a suitable design for evaluating tele-
medicine, which is highly sensitive to local conditions.
For instance randomisation will not ensure that the inter-
vention is separated from the context [2], i.e. that the dis-
tance between the sites and other local costs are equally
distributed in two groups. It is also common in telemedi-
cine research to allow for self-selection. A naturalistic
design or decision modelling might be more appropriate.
The modelling studies in this review provided few details
about both the model employed and the criteria used to
ensure the validity of the primary studies, making it diffi-
cult to assess the robustness of the estimate measures. On
the other hand, extensive sensitivity analyses improved
the external validity of these studies.Cost Effectiveness and Resource Allocation 2009, 7:18 http://www.resource-allocation.com/content/7/1/18
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Whether to use trial-based data or modelling studies
should be seen in relation to the objective of the study and
the viewpoint of those who are expected to use the results.
Some researchers argue that trial-based studies are supe-
rior, while others view them as complementary rather
than alternative approaches [4]. Decisions about whether
to invest in telemedicine should ideally be based on a syn-
thesis of all available data and not just on a single trial. In
telemedicine research, however, there are few studies of
good quality available in the different medical fields
[2,14], which limits the use of decision modelling.
Researchers should comment directly on the transferabil-
ity of their findings [57]. Some studies did acknowledge
limitations, but these were mainly related to internal
validity such as a low sample size and wide confidence
intervals. It is also important to address situation-specific
features that could influence the results, such as local
treatment procedures or organisational structures. Costs
and outcomes of interventions are always associated with
some degree of uncertainty. Uncertainty may be due to
sampling variation in estimates of both costs and out-
comes and it may also be related to the economic model
and the evaluation process [58]. In addition to highly dif-
ferent contexts and local settings, other parameters such as
perspective, assumptions regarding cost and outcome
identification, measurements and valuation may affect
the results. Over half of the studies did not include sensi-
tivity analysis. This limits the usefulness of the cost-effec-
tiveness data as a basis for health system decision-making.
Presenting the cost and outcomes disaggregated in cost-
consequence analyses (CCA) has been suggested as a use-
ful systematic framework in evaluating telemedicine [59].
More than half of the reviewed studies presented their
results using this framework. CCA lists all the different
outcomes together with the costs instead of using a unidi-
mensional outcome measure. This partly overcomes the
challenge of deciding on a common outcome measure in
different telemedicine settings, but severely limits general-
isability. Multidimensional presentation of the conse-
quences can also be difficult to interpret, especially if the
different outcome dimensions move in different direc-
tions [54]. Another challenge is how to value, for exam-
ple, a two-week reduction in waiting time if the
consequences are presented in a descriptive manner.
Other typical benefits claimed for telemedicine that are
difficult to value would include improved quality of serv-
ice, speed of service and transfer of skills. More research is
needed to address these aspects. Hailey (2005) argues that
the one of the immediate needs in economic evaluation of
telemedicine is to improve clarity in the reporting of the
economic findings [18].
Summary and conclusion
For studies in telemedicine, as in economic evaluations of
other medical technologies, it is important to be clear
about the objective, comparators, perspective and study
design. This will make the study transparent and help
readers to decide whether results can apply to their own
settings. Measuring and valuing the costs can be a major
challenge, especially if the telemedicine services involve a
mix of complex delivery systems and technologies.
Aspects that need extra attention include how to handle
shared resources, production capacity, marginal costs and
the use of salaries and charges as proxies for opportunity
costs. For example, one problem with using hospital
accounting systems and charges is that some resources
that are used but not billed may be overlooked. Different
costing patterns may also make results from one study less
adaptable to other settings. Measuring and valuing the
consequences is another key challenge in the evaluation
of telemedicine. Whether to use disease-specific or generic
tools to measure the consequences should be seen in rela-
tion to the objectives and the type of services provided. If
telemedicine technologies are employed to replace an in-
person consultation, disease-specific instruments can be
applied to ensure that the benefits for the patients are
equivalent or better to that of conventional care. On the
other hand, if telemedicine is provided in addition to
existing traditional services for example in home care,
other more generic health measures are more appropriate.
As this paper demonstrates, few economic evaluations of
telemedicine can be trusted to provide reliable informa-
tion for decision-making. The majority of the evaluations
reviewed were not in accordance with standard evaluation
techniques and still have a long way to go before decision-
makers can rely on them to produce valid and reliable
cost-effectiveness data. Such improvement refers prima-
rily to technical aspects and reporting of results. Given the
differences in decision problems, local settings and the
range of analytical choices, it is not surprising that there is
considerable variation in economic evaluations of tele-
medicine. Further research is needed to explore how
much of this variation can be justified and accepted in
telemedicine decision-making. It is also important to
address how economic evaluations of telemedicine can
best take advantage of local constraints and geographical
heterogeneity and at the same time produce valid and reli-
able results.
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